Sanara MedTech (SMTI)

Its soft tissue repair portfolio includes CellerateRX Surgical Powder, a hydrolyzed collagen product used in the management of surgical wounds. Collagen-based products are used by surgeons because collagen plays an important role in the body’s natural wound healing process. Sanara also markets BIASURGE Surgical Solution, a sterile, no-rinse irrigation solution intended for use during procedures where wound cleansing is required.

In bone fusion, the company offers products such as BiFORM Bioactive Moldable Matrix, an osteoconductive implant designed to provide a scaffold that supports new bone growth. It also markets ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix that contains bone-derived progenitor cells and conformable bone fibers. These products are aimed at surgeons working in procedures where bone repair or fusion is needed.

Sanara’s business model centers on developing, acquiring, and commercializing specialized surgical technologies, then selling them into hospitals, ambulatory surgical centers, and physician-led settings. For investors, SMTI is tied to demand for advanced wound management and biologic surgical products, areas where clinical outcomes, reimbursement, surgeon adoption, and distribution reach are key competitive factors.